Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1062

1.

Clinical trials in autism spectrum disorder: evidence, challenges and future directions.

Anagnostou E.

Curr Opin Neurol. 2018 Jan 31. doi: 10.1097/WCO.0000000000000542. [Epub ahead of print]

PMID:
29389748
2.

Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia.

Rickels MR, Perez EM, Peleckis AJ, Alshehabi E, Nguyen HL, Stefanovski D, Rickels K, Teff KL.

Am J Physiol Endocrinol Metab. 2017 Dec 19. doi: 10.1152/ajpendo.00315.2017. [Epub ahead of print]

PMID:
29351487
3.

Metabolic Side Effects in Patients Using Atypical Antipsychotic Medications During Hospitalization.

Dikeç G, Arabaci LB, Uzunoglu GB, Mizrak SD.

J Psychosoc Nurs Ment Health Serv. 2018 Jan 11:1-10. doi: 10.3928/02793695-20180108-05. [Epub ahead of print]

PMID:
29328360
4.

Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies.

Burghardt KJ, Seyoum B, Mallisho A, Burghardt PR, Kowluru RA, Yi Z.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Apr 20;83:55-63. doi: 10.1016/j.pnpbp.2018.01.004. Epub 2018 Jan 8.

PMID:
29325867
5.
6.

Decreased 5-HT2cR and GHSR1a interaction in antipsychotic drug-induced obesity.

Huang XF, Weston-Green K, Yu Y.

Obes Rev. 2018 Mar;19(3):396-405. doi: 10.1111/obr.12638. Epub 2017 Nov 9. Review.

PMID:
29119689
7.

Gestational Weight Gain and Pre-pregnancy Body Mass Index Associated With Second-Generation Antipsychotic Drug Use During Pregnancy.

Freeman MP, Sosinsky AZ, Goez-Mogollon L, Savella GM, Moustafa D, Viguera AC, Cohen LS.

Psychosomatics. 2017 Sep 21. pii: S0033-3182(17)30192-5. doi: 10.1016/j.psym.2017.09.002. [Epub ahead of print]

PMID:
29078988
8.

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome.

Jeon SW, Kim YK.

Int J Mol Sci. 2017 Oct 18;18(10). pii: E2174. doi: 10.3390/ijms18102174. Review.

9.

Artesunate prevents rats from the clozapine-induced hepatic steatosis and elevation in plasma triglycerides.

Li Y, Su R, Xu S, Huang Q, Xu H.

Neuropsychiatr Dis Treat. 2017 Sep 27;13:2477-2487. doi: 10.2147/NDT.S145069. eCollection 2017.

10.

A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension.

Handen BL, Anagnostou E, Aman MG, Sanders KB, Chan J, Hollway JA, Brian J, Arnold LE, Capano L, Williams C, Hellings JA, Butter E, Mankad D, Tumuluru R, Kettel J, Newsom CR, Peleg N, Odrobina D, McAuliffe-Bellin S, Marler S, Wong T, Wagner A, Hadjiyannakis S, Macklin EA, Veenstra-VanderWeele J.

J Am Acad Child Adolesc Psychiatry. 2017 Oct;56(10):849-856.e6. doi: 10.1016/j.jaac.2017.07.790. Epub 2017 Aug 19.

PMID:
28942807
11.

Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders.

Pompili M, Verzura C, Trovini G, Buscajoni A, Falcone G, Naim S, Nardella A, Sorice S, Baldessarini RJ, Girardi P.

Expert Opin Drug Saf. 2018 Feb;17(2):197-205. doi: 10.1080/14740338.2017.1379989. Epub 2017 Sep 26. Review.

PMID:
28902525
12.

Overexpression of Insig-2 inhibits atypical antipsychotic-induced adipogenic differentiation and lipid biosynthesis in adipose-derived stem cells.

Chen CC, Hsu LW, Huang KT, Goto S, Chen CL, Nakano T.

Sci Rep. 2017 Sep 7;7(1):10901. doi: 10.1038/s41598-017-11323-9.

13.

Can melatonin prevent or improve metabolic side effects during antipsychotic treatments?

Porfirio MC, Gomes de Almeida JP, Stornelli M, Giovinazzo S, Purper-Ouakil D, Masi G.

Neuropsychiatr Dis Treat. 2017 Aug 10;13:2167-2174. doi: 10.2147/NDT.S127564. eCollection 2017.

14.

The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study.

Ketter TA, Sachs GS, Durgam S, Lu K, Starace A, Laszlovszky I, Németh G.

J Affect Disord. 2018 Jan 1;225:350-356. doi: 10.1016/j.jad.2017.08.040. Epub 2017 Aug 18.

15.
16.

Ameliorative Effect of Curcumin on Olanzapine-induced Obesity in Sprague-Dawley Rats.

Parasuraman S, Zhen KM, Banik U, Christapher PV.

Pharmacognosy Res. 2017 Jul-Sep;9(3):247-252. doi: 10.4103/pr.pr_8_17.

17.

ErbB signaling antagonist ameliorates behavioral deficit induced by phencyclidine (PCP) in mice, without affecting metabolic syndrome markers.

Tadmor H, Golani I, Doron R, Kremer I, Shamir A.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:322-331. doi: 10.1016/j.pnpbp.2017.08.010. Epub 2017 Aug 14.

PMID:
28818421
18.

The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C.

Lord CC, Wyler SC, Wan R, Castorena CM, Ahmed N, Mathew D, Lee S, Liu C, Elmquist JK.

J Clin Invest. 2017 Sep 1;127(9):3402-3406. doi: 10.1172/JCI93362. Epub 2017 Aug 14.

19.

Atypical antipsychotics for disruptive behaviour disorders in children and youths.

Loy JH, Merry SN, Hetrick SE, Stasiak K.

Cochrane Database Syst Rev. 2017 Aug 9;8:CD008559. doi: 10.1002/14651858.CD008559.pub3. Review.

PMID:
28791693
20.

Synthesis and biological investigation of tetrahydropyridopyrimidinone derivatives as potential multireceptor atypical antipsychotics.

Xiamuxi H, Wang Z, Li J, Wang Y, Wu C, Yang F, Jiang X, Liu Y, Zhao Q, Chen W, Zhang J, Xie Y, Hu T, Xu M, Guo S, Akber Aisa H, He Y, Shen J.

Bioorg Med Chem. 2017 Sep 1;25(17):4904-4916. doi: 10.1016/j.bmc.2017.07.040. Epub 2017 Jul 24.

PMID:
28774576

Supplemental Content

Loading ...
Support Center